Chiraag Kapadia on Investigating Clonal Hematopoiesis After CAR T-cell Therapy

Video

The MD, PhD candidate at Baylor College of Medicine discussed findings from a new study presented at the 2023 Tandem Meetings.

"CAR T treatments and cell therapies in general are becoming better and more curative. So now they're going to be a lot more patients that are in survivorship clinics, where there is a higher risk of getting secondary malignancies and cardiovascular events. So, we wanted to know if increased clonal hematopoiesis is potentially contributing to those survivorship effects.”

As outcomes improve in hematological malignancies with the help of cell therapies, including chimeric antigen receptor (CAR) T-cell therapies, questions remain about the long-term effects of such therapies in patients whose cancer has been eradicated. One such condition exacerbated by cytotoxic chemotherapy is clonal hematopoiesis (CH).

Researchers from Baylor College of medicine, including Chiraag Kapadia, MD/PhD candidate, GS4, investigated CH prevalence in 26 patients previously treated with CD30 CAR T-cell therapy for lymphoma and found that CH occurred frequently in these heavily pretreated patients and increased in clone size following CD30 CAR-T cell therapy. Kapadia presented these data at the 2023 Tandem Meetings |Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, held in Orlando, Florida, February 15-19, 2023.

CGTLive spoke with Kapadia to learn more about CH and its potential effects in cancer survivors. He discussed the study’s findings, more research to be done, and why research post-cell therapy is important as survival past cell therapy starts to lengthen.

REFERENCE
Kapadia CD, Rosas G, Tarrano V, et al. Longitudinal dynamics of clonal hematopoiesis in patients receiving anti-CD30 CAR T-cell therapy. Presented at: 2023 Tandem Meetings, February 15-18, 2023; Orlando, Florida. Abstract #49.

Newsletter

Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.

Recent Videos
Nathan Yozwiak, PhD, the head of research at the GCTI
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira, and Kilian Guse, PhD, the vice president of genetic medicine platforms at Pacira
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira
Jeffrey Chamberlain, PhD
Tami John, MD
Tami John, MD
Tami John, MD
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital
Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine; as well as clinical director of Cancer Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Related Content
© 2025 MJH Life Sciences

All rights reserved.